Overview of the BAK-free travoprost/timolol BAK-free fixed combination

Bibliography

• Friedman DS, Wolfs RC, O'Colmain BJ, Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-8
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
   PubMed Web of Science ®Google Scholar
• Sommer A, Tielsch JM, Katz J, Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The baltimore eye survey. Arch Ophthalmol 1991;109:1090-5
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD, The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20; discussion 829-30
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, Predictors of long-term Progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56
   PubMed Web of Science ®Google Scholar
• Miglior S, Pfeiffer N, Torri V, Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology 2007;114:3-9
   PubMed Web of Science ®Google Scholar
• Tielsch JM, Sommer A, Katz J, Racial variations in the prevalence of primary open-angle glaucoma: the baltimore eye survey. JAMA 1991;266:369-74
   PubMed Web of Science ®Google Scholar
• Quigley HA, West SK, Rodriguez J, The prevalence of glaucoma in a population-based study of Hispanic subjects: proyecto VER. Arch Ophthalmol 2001;119:1819-26
   PubMed Web of Science ®Google Scholar
• Stein JD, Kim DS, Niziol LM, Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology 2011;118(6):1031-7
   PubMedGoogle Scholar
• Miglior S, Torri V, Zeyen T, Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol 2007;144:266-75
   PubMed Web of Science ®Google Scholar
• Bonomi L, Marchini G, Marraffa M, Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology 2000;107:1287-93
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Kass MA, Gordon MO, Gao F, Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol 2010;128:276-87
   PubMedGoogle Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1268-79
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd edition. Dogma; Savona, Italy: 2008
   Google Scholar
• American Academy of Ophthalmology. Primary open-angle glaucoma: Preferred Practice Pattern. American Academy of Ophthalmology; San Francisco: 2005
   Google Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007;24:1007-16
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5
   PubMedGoogle Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 2010;4:1-9
   PubMedGoogle Scholar
• Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 2009;116:S30-6
   PubMedGoogle Scholar
• Tsai JC, McClure CA, Ramos SE, Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
   PubMed Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010;27:837-45
   PubMed Web of Science ®Google Scholar
• Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther 2006;23:511-19
   PubMed Web of Science ®Google Scholar
• Novack GD, Evans R. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization. J Glaucoma 2001;10:483-6
   PubMed Web of Science ®Google Scholar
• Okabe K, Kimura H, Okabe J, Effect of benzalkonium chloride on transscleral drug delivery. Invest Ophthalmol Vis Sci 2005;46:703-8
   PubMed Web of Science ®Google Scholar
• Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm 2002;53:263-80
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines. Br J Ophthalmol 2011;95:1466-9
   PubMed Web of Science ®Google Scholar
• Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490-6
   PubMed Web of Science ®Google Scholar
• Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994;112:1437-45
   PubMed Web of Science ®Google Scholar
• Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008;27:339-43
   PubMed Web of Science ®Google Scholar
• Baffa Ldo P, Ricardo JR, Dias AC, Tear film and ocular surface alterations in chronic users of antiglaucoma medications. Arq Bras Oftalmol 2008;71:18-21
   PubMed Web of Science ®Google Scholar
• de Jong C, Stolwijk T, Kuppens E, Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol 1994;232:221-4
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003;12:486-90
   PubMed Web of Science ®Google Scholar
• Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008;25:743-51
   PubMed Web of Science ®Google Scholar
• Mundorf T, Wilcox KA, Ousler GW III, Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther 2003;20:329-36
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-23
   PubMed Web of Science ®Google Scholar
• Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996;7:80-6
   PubMedGoogle Scholar
• Broadway D, Grierson I, Hitchings R. Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol 1993;77:590-6
   PubMed Web of Science ®Google Scholar
• Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990;108:1543-8
   PubMed Web of Science ®Google Scholar
• Goto Y, Ibaraki N, Miyake K. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol 2003;121:835-9
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010;29:618-21
   PubMed Web of Science ®Google Scholar
• Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 2011;36:391-8
   PubMed Web of Science ®Google Scholar
• Nelson P, Aspinall P, Papasouliotis O, Quality of life in glaucoma and its relationship with visual function. J Glaucoma 2003;12:139-50
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2011;153:1-9
   PubMedGoogle Scholar
• Katz G, Springs CL, Craven ER, Montecchi-Palmer M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol 2010;4:1253-61
   PubMedGoogle Scholar
• Denis P. Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review. Expert Opin Pharmacother 2011;12:463-71
   PubMed Web of Science ®Google Scholar
• Jia Z, shen D, Xu W. Synthesis and antibacterial activities of quaternary ammonium salt of chitosan. Carbohydr Res 2001;333:1-6
   PubMed Web of Science ®Google Scholar
• Whitson JT, Ochsner KI, Moster MR, The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology 2006;113:1333-9
   PubMed Web of Science ®Google Scholar
• Rosenthal R, Henry C, Stone R, Schlech B. Anatomy of a regimen: consideration of multipurpose solutions during non-compliant use. Cont Lens Anterior Eye 2003;26:17-26
   PubMedGoogle Scholar
• Konstas AG, Mikropoulos D, Haidich AB, Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol 2009;93:481-5
   PubMed Web of Science ®Google Scholar
• Konstas AG, Mikropoulos DG, Embeslidis TA, 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. Eye (Lond) 2010;24:1606-13
   PubMed Web of Science ®Google Scholar
• Rhee DJ, Peace JH, Mallick S, A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2008;2:313-19
   PubMedGoogle Scholar
• Schuman JS, Katz GJ, Lewis RA, Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005;140:242-50
   PubMed Web of Science ®Google Scholar
• Teus MA, Miglior S, Laganovska G, Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2009;3:629-36
   PubMedGoogle Scholar
• Gross RL, Sullivan EK, Wells DT, Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%. Clin Ophthalmol 2007;1:317-22
   PubMedGoogle Scholar
• Kitazawa Y, Smith P, Sasaki N, Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye (Lond) 2011;25:1161-9
   PubMed Web of Science ®Google Scholar
• Gross RL, Peace JH, Smith SE, Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 2008;17:217-22
   PubMed Web of Science ®Google Scholar
• Lewis RA, Katz GJ, Weiss MJ, Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007;16:98-103
   PubMed Web of Science ®Google Scholar
• Gandolfi S, Paredes T, Goldberg I, Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol 2012;22:34-44
   PubMed Web of Science ®Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119-26
   PubMed Web of Science ®Google Scholar
• Shedden A, Adamsons IA, Getson AJ, Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2010;248:1757-64
   PubMed Web of Science ®Google Scholar
• Mundorf TK, Ogawa T, Naka H, A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. Clin Ther 2004;26:541-51
   PubMed Web of Science ®Google Scholar
• Bron A, Chiambaretta F, Pouliquen P, Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension. J Fr Ophtalmol 2003;26:668-74
   PubMed Web of Science ®Google Scholar
• Labbe A, Pauly A, Liang H, Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 2006;22:267-78
   PubMed Web of Science ®Google Scholar
• Liang H, Brignole-Baudouin F, Pauly A, Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther 2011;28:311-25
   PubMed Web of Science ®Google Scholar
• Brignole-Baudouin F, Riancho L, Liang H, In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost/timolol fixed combination and latanoprost/timolol fixed combination. J Ocul Pharmacol Ther 2011;27:273-80
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis 2011;17:1806-13
   PubMed Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. Adv Ther 2011;28:501-10
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977;95(4):601-4
   PubMedGoogle Scholar
• Realini T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology 2002;109:1955-6
   PubMed Web of Science ®Google Scholar
• Konstas AG, Tsironi S, Vakalis AN, Intraocular pressure control over 24 h using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta Ophthalmol 2009;87:71-6
   PubMed Web of Science ®Google Scholar
• Asrani S, Zeimer R, Wilensky J, Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134-42
   PubMed Web of Science ®Google Scholar
• Lee PP, Walt JW, Rosenblatt LC, Association between intraocular pressure variation and glaucoma progression: data from a United States chart review. Am J Ophthalmol 2007;144:901-7
   PubMed Web of Science ®Google Scholar
• Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology 2008;115:1123-9; e3
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Hoffman D, Coleman AL, Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111:1627-35
   PubMed Web of Science ®Google Scholar
• Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 2007;114:205-9
   PubMed Web of Science ®Google Scholar
• Liu JH, Kripke DF, Twa MD, Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci 1999;40:2912-17
   PubMed Web of Science ®Google Scholar
• Liu JH, Zhang X, Kripke DF, Weinreb RN. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci 2003;44:1586-90
   PubMed Web of Science ®Google Scholar